Blackrock Neurotech

Executive Summary

Blackrock Neurotech is a privately held pioneer in brain-computer interface (BCI) technology, based in Salt Lake City. Founded in 2008, the company develops implantable neurotechnology platforms aimed at restoring function and independence for individuals with paralysis and severe neurological disorders. Its systems have demonstrated the ability to enable direct thought control of digital devices and robotic limbs. Blackrock Neurotech operates at the intersection of medical devices and neuroscience, with a focus on translating decades of academic research into clinically viable solutions. While the company has not disclosed total funding or valuation, its long history and proven clinical results position it as a key player in the emerging BCI market. The executive summary highlights its potential to address unmet needs in neurorehabilitation, with a conviction score reflecting the high-risk, high-reward nature of the sector and the company's early commercial stage.

Upcoming Catalysts (preview)

• Q4 2026FDA IDE Approval for First-in-Human Trial of Next-Gen BCI System70% success
• Q2 2026Strategic Partnership with Major Rehab Hospital Network60% success
• Q3 2026Publication of Long-Term Safety and Efficacy Data from Existing Cohort80% success